We are live on ! Find out more
TTPH

Tetraphase Pharmaceuticals, Inc.
TTPH

Delisted

TTPH was delisted on the 28th of July, 2020.

Back to rankings

26 hedge funds and large institutions have $2.67M invested in Tetraphase Pharmaceuticals, Inc. in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 16 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

61% less funds holding

Funds holding: 66 → 26 (-40)

68% less capital invested

Capital invested by funds: $8.23M → $2.67M (-$5.56M)

75% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 16

93% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 43

Holders
26
Holders Change
-40
Holders Change %
-60.61%
% of All Funds
0.57%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
16
Closed
43
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$214K
2
TRCT
Tower Research Capital (TRC)
New York
+$10.8K
3
Victory Capital Management
Victory Capital Management
Texas
+$3.06K
4
JP Morgan Chase
JP Morgan Chase
New York
+$1.65K
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$13

Top Sellers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
-$403K
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$396K
3
Northern Trust
Northern Trust
Illinois
-$265K
4
RA
Royce & Associates
New York
-$254K
5
Millennium Management
Millennium Management
New York
-$251K
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
26
Millennium Management
New York
– -$251K -26,136 Closed
Goldman Sachs
27
Goldman Sachs
New York
– -$183K -19,049 Closed
Jane Street
28
Jane Street
New York
– -$122K -12,731 Closed
PP
29
Paloma Partners
Connecticut
– -$115K -12,010 Closed
EDRH
30
Edmond de Rothschild Holding
Switzerland
– -$101K -10,500 Closed
California Public Employees Retirement System
31
California Public Employees Retirement System
California
– -$79K -8,190 Closed
T. Rowe Price Associates
32
T. Rowe Price Associates
Maryland
– -$79K -8,180 Closed
Bank of New York Mellon
33
Bank of New York Mellon
New York
– -$51K -5,271 Closed
Citadel Advisors
34
Citadel Advisors
Florida
– -$50K -5,213 Closed
ARTA
35
A.R.T. Advisors
New York
– -$48K -5,031 Closed
Barclays
36
Barclays
United Kingdom
– -$34K -3,525 Closed
DCC
37
Dow Chemical Company
Michigan
– -$31K -3,250 Closed
LP
38
LMR Partners
United Kingdom
– -$28K -2,881 Closed
State Street
39
State Street
Massachusetts
– -$26K -2,656 Closed
Squarepoint
40
Squarepoint
New York
– -$25K -2,654 Closed
GI
41
GAMCO Investors
Connecticut
– -$24K -2,500 Closed
SAM
42
Sectoral Asset Management
Quebec, Canada
– -$19K -1,991 Closed
QCM
43
Quest Capital Management
Texas
– -$17K -1,750 Closed
TA
44
Teton Advisors
New York
– -$17K -1,750 Closed
GF
45
Gabelli Funds
New York
– -$14K -1,500 Closed
HF
46
HRT Financial
New York
– -$12K -1,251 Closed
AG
47
Aperio Group
California
– -$10K -1,074 Closed
PGFC
48
Peapack-Gladstone Financial Corp
New Jersey
– -$10K -1,000 Closed
FWM
49
Focused Wealth Management
New York
– -$9K -952 Closed
BJL
50
Brighton Jones LLC
Washington
– -$8K -791 Closed
1
2
3

TTPH Hedge Fund Activity: Q3 2019 in Review

26 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Tetraphase Pharmaceuticals, Inc. (TTPH) for Q3 2019, worth a combined $2.67M — down 68% from $8.23M a quarter earlier.

Sellers outnumbered buyers: 43 funds closed out of TTPH and 3 opened new positions — a net loss of 40 holders — while 16 trimmed existing stakes and 4 added.

The largest buyer was Renaissance Technologies, adding an estimated $214K. The largest seller was 683 Capital Management, exiting entirely with an estimated $403K sold.

  • 26 institutional investors held Tetraphase Pharmaceuticals, Inc. (TTPH) as of Q3 2019, down from 66 in Q2 2019.
  • Funds reported $2.67M of Tetraphase Pharmaceuticals, Inc. stock for Q3 2019, down 68% quarter-over-quarter.
  • 3 funds opened new Tetraphase Pharmaceuticals, Inc. positions in Q3 2019 and 43 closed out, a net change of -40 holders.
  • The largest Tetraphase Pharmaceuticals, Inc. buyer in Q3 2019 was Renaissance Technologies, an estimated $214K added.
  • The largest Tetraphase Pharmaceuticals, Inc. seller in Q3 2019 was 683 Capital Management, an estimated $403K sold.

Based on aggregated 13F filings for Q3 2019.